The Federal Trade Commission’s long-running suit against Cephalon Inc. and several generic manufacturers will be heading to trial as a federal judge found that the total payments Cephalon (now Teva Pharmaceutical Industries Ltd.) made to settle Provigil (modafinil) patent infringement suits “greatly exceed saved litigation expenses.”
Teva Pay-For-Delay Plausible; Judge Finds Payments Exceed Litigation Costs
Focused on $300 million in payments Cephalon made to generic firms to settle Provigil patent suits, case is second to proceed to trial since Supreme Court’s Actavis decision.
More from Legal & IP
• By
The Trump Administration requested a dismissal or transfer of a lawsuit seeking to tighten the safety requirements for the abortion pill mifepristone on procedural grounds, which still leaves the administration's position on the case's merits unclear.
• By
Viatris joined Hikma and Amneal, in signing agreements for cash settlements that resolve allegations its practices fueled the US’ deadly opioid epidemic.
• By
The mood at the World Vaccines Congress in Washington, D.C. was bleak given Robert F. Kennedy Jr.’s rise to lead the Trump Administration’s Health and Human Services Department, but vaccine lawyers offered an optimistic outlook and ideas for countering his vaccine agenda.
• By
Eli Lilly is seeking an injunction barring a weight loss clinic from dispensing modified versions of its GLP-1 products.
More from Pink Sheet
• By
England’s health technology assessment institute explains how its sandbox environment is helping to test new evaluation methods for drugs or indications with which it does not have experience, such as metabolic dysfunction-associated steatohepatitis.
• By
The European Medicines Agency, like its counterpart in the US, is increasingly focusing on the use of alternatives to animal testing.
• By
Industry is concerned that Prasad may make regulatory flexibility tougher to obtain for cell and gene therapy, while vaccine and public health advocates are angry about Prasad’s criticisms of US COVID-19 policies.